HC Wainwright Issues Negative Estimate for IOVA Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – HC Wainwright decreased their Q1 2026 EPS estimates for shares of Iovance Biotherapeutics in a report issued on Wednesday, April 22nd. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will earn ($0.22) per share for the quarter, down from their previous forecast of ($0.15). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.77) EPS and FY2027 earnings at ($0.57) EPS.

Several other analysts also recently commented on IOVA. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $2.00 price objective on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. Truist Financial raised shares of Iovance Biotherapeutics to a “hold” rating in a report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Monday, April 6th. Barclays upped their price objective on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Iovance Biotherapeutics in a report on Friday, April 10th. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $8.88.

Iovance Biotherapeutics Price Performance

IOVA stock opened at $3.44 on Friday. The firm’s fifty day simple moving average is $3.71 and its 200-day simple moving average is $2.86. The company has a market capitalization of $1.42 billion, a P/E ratio of -3.07 and a beta of 0.76. Iovance Biotherapeutics has a 12 month low of $1.64 and a 12 month high of $5.63.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.04. The business had revenue of $86.77 million for the quarter, compared to the consensus estimate of $81.61 million. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.54%.

Institutional Trading of Iovance Biotherapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Xponance LLC boosted its stake in Iovance Biotherapeutics by 19.4% during the fourth quarter. Xponance LLC now owns 24,288 shares of the biotechnology company’s stock worth $66,000 after buying an additional 3,950 shares during the period. Raymond James Financial Inc. boosted its stake in Iovance Biotherapeutics by 1.4% during the second quarter. Raymond James Financial Inc. now owns 324,098 shares of the biotechnology company’s stock worth $557,000 after buying an additional 4,618 shares during the period. R Squared Ltd boosted its stake in Iovance Biotherapeutics by 41.4% during the third quarter. R Squared Ltd now owns 16,043 shares of the biotechnology company’s stock worth $35,000 after buying an additional 4,700 shares during the period. Orion Investment Co boosted its stake in Iovance Biotherapeutics by 0.3% during the fourth quarter. Orion Investment Co now owns 1,856,934 shares of the biotechnology company’s stock worth $5,069,000 after buying an additional 5,150 shares during the period. Finally, Flputnam Investment Management Co. boosted its stake in Iovance Biotherapeutics by 35.4% during the third quarter. Flputnam Investment Management Co. now owns 20,289 shares of the biotechnology company’s stock worth $44,000 after buying an additional 5,300 shares during the period. 77.03% of the stock is owned by hedge funds and other institutional investors.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.